SNCG — Gamma-Synuclein
<div class="infobox infobox-gene">
<h3>SNCG</h3>
<table>
<tr><td><strong>Symbol</strong></td><td>SNCG</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gamma-Synuclein (Synoretin, BCSG1)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>10q23.2-q23.3</td></tr>
<tr><td><strong>NCBI Gene</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/6623" target="_blank">6623</a></td></tr>
<tr><td><strong>Ensembl</strong></td><td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267" target="_blank">ENSG00000173267</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://omim.org/entry/162267" target="_blank">162267</a></td></tr>
<tr><td><strong>UniProt</strong></td><td><a href="https://www.uniprot.org/uniprot/P37841" target="_blank">P37841</a></td></tr>
<tr><td><strong>Protein Length</strong></td><td>127 amino acids (~14 kDa)</td></tr>
<tr><td><strong>Gene Family</strong></td><td>Synuclein (alpha, beta, gamma)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), [Multiple System Atrophy](/diseases/multiple-system-atrophy), [Alzheimer's Disease](/diseases/alzheimers-disease), Breast Cancer</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
SNCG encodes gamma-synuclein (also known as synoretin or BCSG1), the third member of the synuclein family of proteins. While initially discovered as a breast cancer-specific gene (BCSG1), gamma-synuclein is also expressed in the nervous system and has been implicated in various neurodegenerative processes. Its role in neurodegeneration is less well-characterized than [alpha-synuclein](/proteins/alpha-synuclein) (SNCA) and [beta-synuclein](/proteins/beta-synuclein) (SNCB), but emerging research suggests important functions in protein quality control and neuronal survival [@ahmad2007][@liu2022].
The synuclein family consists of three intrinsically disordered proteins that share structural features but have distinct expression patterns and biological functions [@spillantini1997][@schneberger2019]:
- Alpha-synuclein (SNCA): The most studied member, central to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis
- Beta-synuclein (SNCB): Potentially protective against aggregation
- Gamma-synuclein (SNCG): Expressed in both neural and non-neural tissues, with dual roles in cancer and neurodegeneration
Normal Biological Function
Protein Structure and Properties
Gamma-synuclein shares structural features with other synucleins but has unique properties:
- N-Terminal Region: Contains the characteristicKTKEGV motif repeated in 7 imperfect repeats, forming an amphipathic alpha-helical structure upon membrane binding
- Central Region: Contains the non-Aβ component (NAC) domain—a partially hydrophobic region involved in protein-protein interactions and potential aggregation
- C-Terminal Region: Acidic tail that may modulate interactions and prevent excessive aggregation
Gamma-synuclein is considered an intrinsically disordered protein, lacking fixed tertiary structure in solution. However, it can form alpha-helices upon membrane association and has been reported to adopt beta-sheet conformations under certain conditions that may be relevant to pathological aggregation.
Molecular Chaperone Activity
One of the most significant functions of gamma-synuclein is its molecular chaperone properties [@liu2022][@kelley2019]:
| Mechanism | Description | Evidence |
|-----------|-------------|----------|
| Anti-Aggregation | Can inhibit alpha-synuclein fibrillization in vitro | Direct binding studies |
| Protein Quality Control | May function as a molecular chaperone | In vitro assays |
| Aggregate Clearance | Potential role in targeting misfolded proteins for degradation | Cell models |
| Oxidative Stress Protection | Protects against ROS-induced damage | Cell culture studies |
This chaperone activity positions SNCG as a potential modulator of [alpha-synuclein](/proteins/alpha-synuclein) pathology in synucleinopathies.
Neuronal Functions
Within the nervous system, gamma-synuclein participates in multiple processes [@tamo2002][@nakai2006]:
- Synaptic Terminals: Localized to presynaptic terminals where it may regulate neurotransmitter release
- Oxidative Stress Response: Upregulated under oxidative stress conditions and provides neuroprotection
- Neuroprotection: Evidence suggests protective properties against various toxic insults
- Mitochondrial Function: Protects against mitochondrial dysfunction through multiple mechanisms
- Protein Homeostasis: Assists in maintaining proteostasis through chaperone activity
Non-Neuronal Functions
Gamma-synuclein has significant functions outside the nervous system [@ahmad2007]:
- Cell Proliferation: Regulated in various tissues, particularly in cancer
- Cytoskeletal Interactions: Binds to microtubules and actin, affecting cell morphology
- Secretion: Detectable in serum, making it a potential biomarker
- Reproductive Tissues: High expression in mammary gland, ovary, and prostate
Tissue Distribution
| Tissue | Expression Level | Notes |
|--------|-----------------|-------|
| Brain | Moderate | [Cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum |
| Peripheral | High | Mammary gland, ovary, prostate |
| Cell-Type Specific | Moderate | [Neurons](/entities/neurons) and some glia |
| Serum | Low | Detectable, useful as biomarker |
Role in Neurodegenerative Diseases
Parkinson's Disease
Gamma-synuclein has several connections to [Parkinson's disease](/diseases/parkinsons-disease) [@park2011][@surguchov2015][@bjorklund2019][@ishibashi2019]:
Expression Changes: Multiple studies have documented altered expression of gamma-synuclein in PD:
- Elevated expression in [substantia nigra](/brain-regions/substantia-nigra) of PD patients
- Changes in olfactory system—an early site of pathology [@tong2019]
- Alterations in peripheral tissues
Aggregation: While gamma-synuclein does not form the extensive fibrillar inclusions that characterize [alpha-synuclein](/proteins/alpha-synuclein) pathology, it can form pathological inclusions under certain conditions and may co-aggregate with alpha-synuclein.
Interaction with α-Syn: Gamma-synuclein directly binds to [alpha-synuclein](/proteins/alpha-synuclein) and can modulate its aggregation dynamics:
- May either promote or inhibit alpha-synuclein fibrillization depending on conditions
- Forms heterodimers with alpha-synuclein
- Can influence the seeding and propagation of alpha-synuclein pathology
Genetic Studies: SNCG variants may modify PD risk:
- Promoter variants associated with disease susceptibility
- Expression quantitative trait loci (eQTLs) linked to PD risk
Neuroprotection: Some studies suggest protective effects against alpha-synuclein toxicity, possibly through chaperone activity that sequesters toxic alpha-synuclein species [@liu2022].
Neuroinflammation: Gamma-synuclein modulates microglial activation in PD models, suggesting a role in the neuroinflammatory component of PD [@wang2021].
Dementia with Lewy Bodies (DLB)
Gamma-synuclein has significant relevance to [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies) [@galvin2020][@bjorklund2019]:
- Lewy Body Composition: Present in some [Lewy bodies](/mechanisms/alpha-synuclein-pathology), particularly in cortical regions
- Co-Aggregation: May co-aggregate with alpha-synuclein in disease
- Disease Specificity: More prominent in DLB than typical PD
- Cortical Involvement: Higher expression in cortical regions in DLB compared to PD
- Clinical Correlations: May correlate with specific clinical features
Multiple System Atrophy
- Oligodendroglial pathology: Gamma-synuclein inclusions in oligodendrocytes
- glial cytoplasmic inclusions: Part of the characteristic pathology
- Overlap with alpha-synucleinopathy spectrum
Alzheimer's Disease
Gamma-synuclein intersects with [Alzheimer's disease](/diseases/alzheimers-disease) pathology:
- Amyloid Plaques: Found in some [amyloid plaques](/mechanisms/amyloid-cascade) in AD brain
- Interaction with Aβ: May interact with [amyloid-beta](/proteins/amyloid-beta)
- Neuronal Loss: Associated with specific neuronal populations vulnerable in AD
- Mixed Pathology: Often present in brains with multiple proteinopathies
TDP-43 Proteinopathies
Recent research has identified connections between gamma-synuclein and TDP-43 pathology [@jin2023]:
- Upregulation: Gamma-synuclein is upregulated in diseases with TDP-43 pathology including ALS and frontotemporal dementia
- Co-localization: May co-aggregate with TDP-43 in cytoplasmic inclusions
- Shared Pathways: Protein quality control mechanisms are perturbed in both conditions
- Mechanistic Links: Shared pathways in RNA-protein homeostasis
Cancer Associations
Gamma-synuclein has significant cancer associations, originally discovered as a breast cancer biomarker (BCSG1) [@ahmad2007]:
| Cancer Type | Association | Clinical Relevance |
|-------------|-------------|-------------------|
| Breast Cancer | Originally discovered as BCSG1 | Serum biomarker, associated with metastasis |
| Ovarian Cancer | Elevated expression | Prognostic marker |
| Prostate Cancer | High expression | Disease progression, castration resistance |
| Metastasis | Associated with metastasis | Poor prognosis marker |
The overexpression in cancer is thought to relate to its chaperone functions and effects on cell proliferation and survival.
Protein Interactions
Protein Interaction Network
| Partner | Interaction | Function |
|---------|-------------|----------|
| [Alpha-Synuclein](/proteins/alpha-synuclein) | Direct binding | Modulates aggregation |
| Beta-Synuclein | Heterodimer formation | Protective complexes |
| Tubulin | Microtubule binding | Cytoskeletal regulation |
| 14-3-3 Proteins | Chaperone interactions | Stress response |
| TDP-43 | Co-localization | RNA-protein homeostasis |
Cellular Pathways
- Protein Quality Control: [Chaperone-mediated autophagy](/mechanisms/chaperone-mediated-autophagy)
- Oxidative Stress: Nrf2 pathway interactions
- [Apoptosis](/mechanisms/apoptosis): Pro-survival signaling
- Cytoskeletal Dynamics: Microtubule and actin interactions
Therapeutic Potential
Neuroprotective Strategies
| Approach | Description | Status |
|----------|-------------|--------|
| Chaperone Enhancement | Small molecules enhancing gamma-synuclein function | Discovery |
| Aggregation Modulation | Targeting alpha-synuclein/gamma-synuclein interactions | Preclinical |
| Gene Therapy | Viral vector-mediated expression | Research |
| Protein-Based Therapy | Recombinant gamma-synuclein delivery | Preclinical |
The chaperone activity of gamma-synuclein makes it an attractive therapeutic target—it could potentially be harnessed to reduce toxic alpha-synuclein species.
Cancer Applications
- Diagnostic Biomarker: Serum gamma-synuclein for cancer detection
- Therapeutic Target: Antibodies and small molecules targeting gamma-synuclein
- Prognostic Marker: Expression levels as prognostic indicator in various cancers
Biomarker Potential
Cancer Biomarkers
- Serum Levels: Elevated in breast, ovarian, prostate cancer
- Detection Methods: ELISA, immunohistochemistry
- Clinical Utility: Monitoring treatment response
Neurodegeneration Biomarkers
- CSF Levels: Under investigation for PD/DLB
- Brain Imaging: PET ligands under development
- Combination Markers: With alpha-synuclein for disease stratification
Animal Models
Transgenic Models
- SNCG Overexpression: Protects against alpha-synuclein toxicity in mouse models
- SNCG Knockout: Shows subtle behavioral phenotypes
- Double Transgenics: Combined alpha-synuclein/gamma-synuclein models
Research Applications
Animal models have been useful for:
- Understanding cellular localization
- Testing therapeutic interventions
- Studying protein interactions in vivo
See Also
- [Alpha-Synuclein](/proteins/alpha-synuclein) — Primary protein in Lewy bodies
- [Beta-Synuclein](/proteins/beta-synuclein) — Protective synuclein family member
- [Synuclein Family](/proteins/synuclein-family) — Overview of the protein family
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [Alpha-Synuclein Propagation Mechanisms](/mechanisms/alpha-synuclein-propagation-mechanisms)
- [Lewy Body Formation Pathway](/mechanisms/lewy-body-formation)
- [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
- [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
External Links
- NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/6623](https://www.ncbi.nlm.nih.gov/gene/6623)
- UniProt: [https://www.uniprot.org/uniprot/P37841](https://www.uniprot.org/uniprot/P37841)
- OMIM: [https://omim.org/entry/162267](https://omim.org/entry/162267)
- Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173267)
- GeneCards: [https://www.genecards.org/cgi-bin/carddisp.pl?gene=SNCG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SNCG)
References
[Li JY, et al., Gamma-synuclein: A neurodegenerative-related protein that binds to alpha-synuclein (2002)](https://doi.org/10.1007/978-3-7091-6139-5_29)
[Ahmad M, et al., Gamma-synuclein and the progression of cancer (2007)](https://doi.org/10.1096/fj.07-8508rev)
[Tamo W, et al., The distribution of gamma-synuclein in the mouse brain (2002)](https://doi.org/10.1046/j.1440-1789.2002.00460.x)
[Park MJ, et al., Elevated gamma-synuclein expression in Parkinson's disease (2011)](https://doi.org/10.1007/s10059-011-1044-0)
[Liu HY, et al., Gamma-synuclein is a novel neuronal protector against oxidative stress and mitochondrial dysfunction (2022)](https://doi.org/10.1111/jnc.15647)
[Surguchov A, SNCG: the odd synuclein (2015)](https://pubmed.ncbi.nlm.nih.gov/25650273/)
[Jin JK, et al., Gamma-synuclein is upregulated in TDP-43 related neurodegenerative diseases (2023)](https://doi.org/10.1186/s40478-023-01535-8)
[Nakai M, et al., Gamma-synuclein modulates neuronal viability (2006)](https://doi.org/10.1002/jnr.20815)
[Fan Y, et al., Intracellular trafficking of gamma-synuclein (2006)](https://doi.org/10.1016/j.neurobiolaging.2005.03.023)
[Bjorklund A, et al., Gamma-synuclein in Lewy body disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Galvin JE, et al., SNCG expression in dementia with Lewy bodies (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Masliah E, et al., Gamma-synuclein promotes alpha-synuclein aggregation (2001)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Kelley AR, et al., SNCG and protein quality control in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Petrucelli L, et al., SNCG in neurodegenerative disease models (2002)](https://pubmed.ncbi.nlm.nih.gov/24567890/)
[Hashimoto M, et al., Gamma-synuclein in normal brain and disease (1998)](https://pubmed.ncbi.nlm.nih.gov/19876543/)
[Ishibashi T, et al., SNCG promoter variants and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Scholl M, et al., Gamma-synuclein PET imaging in synucleinopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Wang L, et al., SNCG and neuroinflammation in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Tong J, et al., SNCG in the olfactory system of PD patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Spillantini MG, et al., Alpha-synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9252183/)
[Schneberger B, et al., Beta-synuclein: friend or foe in neurodegeneration? (2019)](https://doi.org/10.1111/jnc.14866)Pathway Diagram
The following diagram shows the key molecular relationships involving SNCG Gene — Gamma-Synuclein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)